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ABSTRACT
Background:  Chronic delta hepatitis is the most severe form of viral hepatitis, for 
which interferon administration is the only available treatment. However, the eﬃcacy 
of interferon treatment is aﬀected by the dose and duration of treatment, and relapse 
rates are high. 
Objectives: In this study, we sought to evaluate the eﬃcacy of treatment with pegylated 
interferon and observe the relapse rates of delta hepatitis after treatment.
Patients and Methods: Forty-six patients with chronic delta hepatitis were retrospec-
tively studied between January 2002 and December 2010. Patients were evaluated for 
biochemical, virological, and histological responses. They were then followed-up for 
at least 1 year after discontinuation of the treatment.
Results: All the 46 patients in the study received PEG-IFN therapy. Of the 46 patients, 
25 were treated with PEG-IFN for 1 year and 21 were treated for 2 years. Sixteen patients 
(34.7%) showed a biochemical response, 27 (58.6%) showed a virological response, and 
39 (84.7%) showed a histological response. Sustained virological and biochemical re-
sponses were achieved in 41% and 47.8% of the patients, respectively. Sixteen (84.2%) 
patients of the 19 with high levels of hepatitis delta virus RNA (HDV RNA) (HDV RNA 
level > 1 × 105) and 10 (71.4%) of the 14 patients with high titers of hepatitis B surface an-
tigen (HbsAg) (HbsAg > 102 IU/mL) at the beginning of the treatment showed relapse 
after treatment.
Conclusions: We found no signiﬁcant diﬀerences between 1-year and 2-year treatments. 
However, the relapse rate was lower in the 2-year treatment group. Higher HDV RNA 
and HbsAg levels before treatment were associated with higher relapse rates. Younger 
age was a signiﬁcant factor in predicting response.
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  Implication for health policy/practice/research/medical education:
There are still many unresolved questions regarding delta hepatitis. This study aims to  investigate every aspect of delta hepatitis and 
recommended all clinicians engaged in the treatment of patients with hepatitis delta.
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1. Background
Chronic delta hepatitis (CDH) is the least common, but 
the most severe, form of viral hepatitis. It is caused by 
hepatitis D virus (HDV), which is a defective RNA virus 
that requires the helper function of hepatitis B virus 
(HBV) for its assembly and transmission (1, 2). Worldwide, Hepat Mon. 2011;11(9):731-735
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it has been estimated that 15 million HBsAg carriers are 
infected with HDV. These patients pose a major therapeu-
tic challenge, because most of them have advanced liver 
disease (2). CDH may lead to cirrhosis within 2 years in 
10–15% of patients and may be frequently associated with 
hepatocellular carcinoma (3). Despite recent advances 
in the treatment of chronic viral hepatitis, therapy of 
chronic hepatitis D is not yet satisfactory (4). In partic-
ular, the unusual features of HDV, combined with the 
limited understanding of its unconventional replicative 
cycle and its high pathogenic potential, make this virus 
an extremely diﬃcult target for antiviral therapy (2). 
Interferon-alpha is the only therapeutic agent currently 
available for the treatment of chronic hepatitis D and is 
also the only licensed drug for CDH (4). However, the rate 
of relapse is high and the eﬃcacy of treatment is related 
to the dose and duration of treatment (2, 4).
2. Objectives
In the current study, we aimed to evaluate the biochemi-
cal, virological, and histopatholgical responses of chron-
ic delta hepatitis patients to interferon therapy and to 
determine the eﬃcacy of pegylated interferon (PEG-IFN) 
treatment in chronic delta hepatitis. We also monitored 
the relapse rate of delta hepatitis after treatment.
3. Patients and Methods
3.1. Patients and Study Settings
Chronic hepatitis B is endemic, and delta hepatitis is 
a common infection in the Southeastern part of Turkey. 
Dicle University and Diyarbakir State Hospital are the 2 
major hospitals serving this region. We retrospectively 
investigated 46 patients with CDH who received treat-
ment and follow-up care in these 2 medical centers from 
January 2002 to December 2010. All patients underwent 
a thorough clinical examination and provided detailed 
medical history. We enrolled patients who were positive 
for HbsAg and HDV antibodies (IgG-anti-HDV) and posi-
tive for serum HDV RNA for at least 6 months, and had 
chronic hepatitis, as assessed by liver histology. Other in-
clusion criteria were as follows: age > 18 years; compen-
sated liver function; no previous use of any antiviral ther-
apy; correlation with clinical evaluation; daily alcohol 
consumption < 50 g; absence of contraindication to an-
tiviral treatment, particularly platelet and polymorpho-
nuclear counts ≥ 75.000/mm3 and 1500/mm3, respective-
ly; absence of coinfections with hepatitis C virus (HCV) 
or human immunodeﬁciency virus (HIV); and absence 
of hepatic decompensation or hepatocellular carcinoma 
(5). Informed consent was obtained from all patients 
who participated in the study. This study was approved 
by the Ethics Committee of the Dicle University and Ad-
ministrative Committee of the Diyarbakir State Hospital. 
The study protocol conforms to the ethical guidelines of 
the 1975 declaration of Helsinki.
3.2. Methods
The diagnosis of CDH was based on the presence of an-
tibodies to the hepatitis delta antigen in the serum and 
hepatitis delta virus RNA in the serum. All patients were 
also positive for HbsAg. Serum HDV RNA and HBV DNA lev-
els were determined by a commercial quantitative PCR 
assay (ABI Prism 7700 Sequence Detection System- real 
time PCR, USA). Routine serological tests, such as assays 
for serum alanine (ALT) and aspartate (AST) aminotrans-
ferase, direct and total bilirubin, albumin, prothrombin 
time, complete blood counts, and α-fetoprotein (AFP), 
were performed by standard methods. Liver ultrasound 
was performed for all patients. Necroinﬂammation and 
ﬁbrosis were assessed with the Knodell histology activity 
index (HAI) scoring system and the Ishak modiﬁcation 
of this system. All biopsy samples with at least 3 portal 
areas were evaluated to be underscored for necroinﬂam-
mation and ﬁbrosis. The pathologist was blinded to the 
patients’ clinical outcomes and biopsy sequence.
3.3. Deﬁnitions
Alanine aminotransferase normalization and HDV RNA 
negativity at the end of treatment and at the end of the 
follow-up period were primary endpoints of the study (5, 
6). A viral load reduction greater than 3 logs in the ﬁrst 
3 months of treatment was deﬁned as early virological 
response (EVR). Sustained virological response (SVR) was 
deﬁned as undetectable serum HDV RNA 1 year after dis-
continuation of the last treatment. Relapse was deﬁned as 
reappearance of serum HDV RNA after treatment. Based 
on the ﬁnal virological response, patients were divided 
into SVR and non-SVR groups. Patients who relapsed af-
ter the achievement of the end-of-treatment response 
were classiﬁed as non-SVR. A biochemical response was 
deﬁned as normal serum ALT levels at the end of treat-
ment or during follow-up. A relapse was deﬁned as an 
increase in serum ALT levels to more than 1.5 times the 
upper limit of normal after a biochemical response (5, 6). 
The endpoints in histologic improvement were; ≥2-point 
decrease in the Knodell necroinﬂammation score, and 
no worsening of the ﬁbrosis score.
3.4. Patient Treatment and Follow-up
Pegylated Interferon alpha-2a (PEGASYS, Roche) was ad-
ministered subcutaneously at a dose of 180 mcg once a 
week for 48 weeks in 25 patients and for 96 weeks in 21 
patients. The injections were reduced or suspended for 
a while if adverse eﬀects occurred. Outpatients returned 
for control visits at 2-month intervals. At the control vis-
its, the following assessments were performed; complete 
physical examination, biochemical tests, tests for HDV 
RNA, HBV DNA, antibodies to the hepatitis delta antigens, 
complete blood count, serum AFP and abdominal ultra-
sonography. The length of the study was calculated from 
the starting date of antiviral therapy to the last follow-up 
visit. Liver-related complications (ascites, upper gastro-Hepat Mon. 2011;11(9):731-735
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intestinal bleeding, and hepatic encephalopathy) were 
considered as an endpoint in all patients. Ascites was 
diagnosed by clinical examination and/or ultrasound 
detection. Porto-systemic encephalopathy was deﬁned 
by clinical parameters. The source of gastro-esophageal 
bleeding was conﬁrmed by endoscopy, whenever pos-
sible (7).
3.5. Statistical Analysis
Baseline characteristics and measures of clinical and 
demographic predictors were summarized using the 
mean, median, standard error, standard deviation (SD), 
and minimum and maximum values. The results were 
expressed in terms of hazard ratios with 95% conﬁdence 
intervals (CI). All analyses were performed using SPSS 
15.0 program (SPSS 15.0 for Windows Evaluation Version 
Release 15.0; 06 September 2006). The chi-square test was 
used in the evaluation of diﬀerent variables. A P < 0.05 
was considered statistically signiﬁcant.
4. Results
Forty-six patients with a mean age of 35.67 ± 11.3 years 
(range, 20–58 years) were included in our study. Of the 46 
patients, 11 (23.9%) were women and 35 (76%) were men. 
Twelve patients (26%) were HbsAg-positive. Six of the 
HbeAg-positive patients were in the group that received 
treatment for 1 year while the rest were in the group that 
was treated for 2 years. The mean HDV RNA level was 7.05 
× 105 (± 3.52 × 105[SD]). All the patients received PEG-IFN 
treatment and completed the treatment. Three of the 
patients who were treated with PEG-IFN for 1 year and 2 
of the patients who were treated for 2 years completed 
their treatment by taking half-dose PEG-IFN therapy for 
certain time periods, because of the adverse eﬀects of the 
treatment.
Biochemical response was observed in 9 patients (36%) 
in the 1-year treatment group and in 7 patients (33.3%) in 
the 2-year treatment group. The mean ALT level decreased 
from 109.16 ± 64.7 to 52.16 ± 30.1 (P < 0.001) in the 1-year 
treatment group at the end of therapy (EOT), whereas it 
was decreased from 136.19 ± 91.12 to 73.76 ± 63.8 (P < 0.01) 
in the 2-year treatment group at the EOT. The mean AST 
level decreased from 69.8 ± 28.6 to 40.3 ± 21.2 (P = 0.0001) 
in the 1-year treatment group, while it decreased from 
73.9 ± 30.7 to 46.0 ± 38.1 (P = 0.005) in the 2-year treatment 
group at the EOT.
Virological response was observed in 13 patients (52%) in 
the 1-year treatment group, and in 14 patients (66.6%) in 
the 2-year treatment group at the EOT. Among patients 
showing virological responses, 3 patients in the 1-year 
treatment group and 2 patients in the 2-year treatment 
group had elevated ALT levels during the follow-up pe-
riod. The mean HDV RNA level decreased from 2.24 × 105 
to 1.4 × 103 (P = 0.008) and from 1.27 × 105 to 3.7 × 103 (P = 
0.003) in the 1- and 2-year treatment groups, respectively, 
at the EOT. At the end of 48 weeks of follow-up, serum 
HDV RNA was absent in 27 patients (58.6%), and both HBV 
DNA and HDV RNA were absent in 26 patients (56.5%). 
Sixteen (84.2%) of the 19 patients with high levels of HDV 
RNA (HDV RNA level > 1 × 105) and 10 (71.4%) of the 14 pa-
tients with high titers of HbsAg (> 102 IU/mL) at the begin-
ning of the treatment showed relapse after treatment (P 
< 0.0001). Of the 46 patients, 14 (56%) of the 1-year treat-
ment group and 11 (52.3) of the 2-year treatment group 
had EVR. In EVR patients, the mean ALT level decreased 
from 133.15 ± 86.4 to 61.41 ± 42.00 (P < 0.0001), and the 
baseline Knodell score decreased from 11.19 ± 2.209 to 
6.65 ± 1.495 (P < 0.0001). Early virological response to 
PEG-IFN was found to correlate with sustained biochemi-
cal response and amelioration of the necroinﬂammation 
scores of the liver (P < 0.0001). Sustained virological and 
biochemical responses were observed in 19 (41%) and 22 
(47.8%) patients in the 1- and 2-year treatment groups, re-
spectively. During the follow-up period, of the 19 patients 
showing SVR, 9 had clinical complaints and 7 had bio-
chemical ﬂuctuations, while of the 27 non-SVR patients 
(16 in the 1-year and 11 in the 2-year treatment groups, 
respectively), 25 had clinical complaints and 24 had bio-
chemical ﬂuctuations. We observed more clinical com-
plaints and biochemical ﬂuctuations in non-SVR patients 
than in SVR patients (P < 0.001).
Of the 46 HDV patients, 26 (56.6%) were younger than 35 
years, and 20 (43.4%) were older than 35 years. The mean 
HDV RNA level decreased from 1.33 × 106 to 6.7 × 103 (P < 
0.001) in younger patients, while it decreased from 1.4 × 
106 to 1.6 × 105 (P = 0.217) in older patients. The baseline 
Knodell score decreased from 9.85 ± 2.111 to 6.92 ± 2.208 
(P < 0.0001) in younger patients and from 10.05 ± 2.282 
to 8.2 ± 1.905 (P = 0.01) in older patients. Thus, at the end 
of treatment, younger patients (< 35 years old) with CDH 
showed better virological and histological improvement 
than older CDH patients (P < 0.001).
The baseline Knodell score decreased from 9.64 ± 2.325 
to 7.0 ± 1.756 (P = 0.0001) in the 1-year treatment group 
and from 10.29 ± 1.953 to 7.14 ± 2.476 (P = 0.0001) in the 
2-year treatment group. No signiﬁcant diﬀerence was ob-
served in histological response rates between the 1-year 
and 2-year treatment groups. No signiﬁcant diﬀerence 
was observed in ﬁbrosis scores. Our patients did not de-
velop liver decompensation or HCC. None of the patients 
lost HbsAg. Seroconversion from HBsAg to anti-HBs was 
not documented in any of the patients. Seroconversion 
from HbeAg to anti-HBe was observed in 7 of the 12 pa-
tients.
5. Discussion
Vaccination against HBV provides protection against 
HDV, but no eﬀective HDV vaccine has been developed to 
protect HbsAg-carriers (8). The course of CDH is generally 
more severe and patients are generally asymptomatic. 
Clinically, CDH can manifest as late-stage complications, 
such as cirrhosis. Alpha-interferon still remains the only 
available therapeutic agent for treating this disease (8). Hepat Mon. 2011;11(9):731-735
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However, there has been controversy regarding the dose, 
duration of therapy, and treatment response-rates in 
CDH. Therefore, the current study is one of the largest 
studies (n = 46) comparing the eﬃcacy of 1- and 2-year 
PEG-IFN treatment protocols for CDH patients and exam-
ining every aspect of the therapy, including the duration 
of therapy, biochemical, virological, and histological 
responses of the patients, and the outcome of the treat-
ment. In Turkey, there are no reports for patients treat-
ed for more than 2 years, because the cost of long-term 
therapy in CDH is not payable by the Government. Hence, 
these are the groups we compared in our study.
Yurdaydin et al. also compared patients receiving 1-year 
and 2-year treatments in Turkey and reported that 2 years 
of treatment does not appear to increase sustained re-
sponse rates in comparison with 1 year of treatment (9). 
However, Gunsar et al reported that 2-year treatment is 
better than 1-year treatment (10). We investigated 46 
CDH patients, a large group for CDH, and observed that 
there is not much diﬀerence between 1-year and 2-year 
treatments in terms of virological, histological, and bio-
chemical responses. Long-term PEG-IFN therapy might 
be more eﬃcacious (9, 11, 12). Available trials indicate that 
high doses of interferon and a long duration of therapy 
were associated with a better biochemical response and 
improvement in liver histology (11). To date, it seems that 
in patients who do respond to interferon therapy, ther-
apy must be extended as long as possible. This seems to 
be the only treatment choice if the patients can tolerate 
the adverse eﬀects of pegylated interferon therapy, and 
monitoring these patients for a sustained response is 
mandatory.
Yurdaydin  et al. reported sustained virological and 
biochemical response rates of 9% and 13%, respectively 
(9). Gunsar et al. found virological and biochemical re-
sponse rates at the end of therapy to be 50% and 60%, re-
spectively (10). Castelnau et al treated CHD patients with 
PEG-IFN-alpha 2b, 1.5 µg/kg weekly for 12 months, and 
reported an SVR of 43% and biochemical response rates 
of 57% (13). Niro et al found virological and biochemical 
response rates at the EOT to be 19% and 37% and sustained 
virological and biochemical response rates to be 21% and 
26%, respectively (14). However, in 2 other series of pa-
tients treated with the same PEG-interferon, an SVR was 
obtained only in 17% and 21% of the patients (15, 16). The re-
sults of the current study appear to show slightly higher 
virological, biochemical, and histological response rates, 
at 27 (58.6%), 16 (34.7%), and 39 (84.7%) at the EOT, and sus-
tained virological and biochemical response rates of 41% 
and 47.8%, respectively. Moreover, we observed more clin-
ical complaints and biochemical ﬂuctuations in non-SVR 
patients than in SVR patients.
We found that younger CDH patients who received the 
PEG-IFN treatment have a better prognosis, in terms of 
histological and virological responses, than older CDH 
patients. We have not seen other reports describing a 
better prognosis in younger patients. In previous stud-
ies, it was reported that patients with a shorter duration 
of CDH may respond better to therapy, even though clear 
predictors of response have not yet been identiﬁed (2, 
10). Moreover, we found a signiﬁcant correlation between 
early virological response to PEG-IFN and sustained bio-
chemical response and amelioration of necroinﬂamma-
tion scores of the liver. In recent reports, authors empha-
sized the importance of EVR in predicting the cases that 
may need extended treatment (4, 13-15).
One of the striking factors in our study was that higher 
HDV RNA and HbsAg levels were associated with higher 
relapse rates in CDH and that the 2-year treatment was 
not superior to the 1-year treatment. According to our 
study, an early virological response to PEG-IFN is associ-
ated with sustained biochemical response and ameliora-
tion in necroinﬂammation scores of the liver. Younger 
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